15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering InspireMD Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.00 to $3.00, so the covering firms are broadly aligned. The average target of $3.00 sits 221% above the current $0.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to InspireMD Inc.
As of Aug, 1 of 1 firms rate NSPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NSPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.14 – $-0.12 · 3 analysts · -7% YoY
Next period, 3 analysts expect InspireMD Inc to earn $-0.13 a share (range $-0.14 – $-0.12), versus $-0.14 a year earlier. Full-year consensus is $-0.45, growing to $-0.48 the year after.
REVENUE · NEXT QUARTER
$2.7M
Range $2.3M – $3.0M · 3 analysts · -16% YoY
Revenue is expected to reach $2.7M (range $2.3M – $3.0M), -15.6% year-over-year. Full-year consensus is $9.8M, rising to $20.1M next year.
Top analysts covering InspireMD Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NSPR.
#1
Anthony Vendetti
Maxim Group · Rank #350
Buy
$4.00+328.5% to target
Overall win rate
29%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #381
Buy
$5.00+435.7% to target
Overall win rate
26%
+ Follow
#3
Adam Maeder
Piper Sandler
Buy
$3.00+221.4% to target
Coverage
—
+ Follow
NSPR stock forecast FAQ
What is NSPR's average 12-month price target?+
The 1 analysts with a live target average $3.00 for InspireMD Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low.
Is NSPR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover NSPR?+
1 analysts have an active rating on InspireMD Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering NSPR?+
Among analysts who currently cover NSPR, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $4.00 target.
What is InspireMD Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.14 – $-0.12) across 3 analysts. Full-year EPS is projected at $-0.45, rising to $-0.48 the following year.
How much revenue is InspireMD Inc expected to report next quarter?+
Consensus revenue is $2.7M (range $2.3M – $3.0M). Full-year revenue is projected at $9.8M, growing to $20.1M next year.
Have analysts been upgrading or downgrading NSPR lately?+
As of Aug, 1 of 1 firms rate NSPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NSPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
